who we are
Angion is a clinical stage biopharmaceutical company
focused on acute kidney injury, a potentially life-threatening
condition without therapeutic options.
If you wish to learn more about enrolling in our Phase 3 trial studying the safety and efficacy of ANG-3777
OUR LEAD CLINICAL ASSET
THE SCIENCE BEHIND
ANG-3777 is engineered to mimic the biological activity of HGF in order to address the timing mismatch of HGF levels and c-MET availability, which may activate this important repair pathway subsequently promoting tissue repair and possible improved organ function.*
*ANG-3777 is currently being studied in clinical trials to determine if it is safe and effective. It is not yet approved for use by any regulatory agency globally.